Cited by 570Ethics in Clinical ResearchRace, Genetics, and SocietyStatistical Methods in Clinical Trials

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018

Open access

Loree, Jonathan M., Anand, Seerat, Dasari, Arvind, Unger, Joseph M., Gothwal, Anirudh, Ellis, Lee M., Varadhachary, Gauri, Kopetz, Scott, Overman, Michael J., Raghav, Kanwal·2019·JAMA Oncology

DOI 10.1001/jamaoncol.2019.1870PMC PMC6696743

Open this paper in CoChat — free account Open PDF

Abstract

IMPORTANCE: Representative racial/ethnic participation in research, especially in clinical trials that establish standards of care, is necessary to minimize disparities in outcomes and to uphold societal equity in health care. OBJECTIVE: To evaluate the frequency of race reporting and proportional race representation in trials supporting US Food and Drug Administration (FDA) oncology drug approvals. DESIGN, SETTING, AND PARTICIPANTS: Database study of all reported trials supporting FDA oncology drug approvals granted between July 2008 and June 2018. Primary reports of trials were obtained from PubMed and ClinicalTrials.gov. Food and Drug Administration approvals were identified using the FDA archives. The US population-based cancer estimates by race were calculated using National Cancer Institute-Surveillance, Epidemiology, and End Results and US Census databases. MAIN OUTCOMES AND MEASURES: Primary outcomes were the proportion of trials reporting race and the proportion of patients by race participating in trials. Secondary outcomes included race subgroup analyses reporting and gaps between race proportion in trials and the US population. Descriptive statistics, Fisher exact, and χ2 tests were used to analyze the data. Proportions and odds ratios (OR) with 95% CIs were reported. RESULTS: Among 230 trials with a total of 112 293 participants, 145 (63.0%) reported on at least 1 race, 18 (7.8%) documented the 4 major races in the United States (white, Asian, black, and Hispanic), and 58 (25.2%) reported race subgroup analyses. Reporting on white, Asian, black, and Hispanic races was included in 144 (62.6%), 110 (47.8%), 88 (38.2%), and 23 (10.0%) trials, respectively. Between July 2008 and June 2013 vs July 2013 and June 2018, the number of trials reporting race (45 [56.6%] vs 100 [67.1%]; OR, 1.63; 95% CI, 0.93-2.87; P = .09) and race subgroup analysis (13 [16.1%] vs 45 [30.2%]; OR, 2.26, 95% CI, 1.16-4.67; P = .03) changed minimally and varied across races. Whites, Asians, blacks, and Hispanics represented 76.3%, 18.3%, 3.1% and 6.1% of trial participants, respectively, and the proportion for each race enrolled over time changed nominally (blacks, 3.6% vs 2.9% and Hispanics, 5.3% vs 6.7%) from July 2008 to June 2013 vs July 2013 to June 2018. Compared with their proportion of US cancer incidence, blacks (22% of expected) and Hispanics (44% of expected) were underrepresented compared with whites (98% of expected) and Asians (438% of expected). CONCLUSIONS AND RELEVANCE: Race and race subgroup analysis reporting occurs infrequently, and black and Hispanic races are consistently underrepresented compared with their burden of cancer incidence in landmark trials that led to FDA oncology drug approvals. Enhanced minority engagement is needed in trials to ensure the validity of results and reliable benefits to all.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1001/jamaoncol.2019.1870

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Unequal treatment: confronting racial and ethnic disparities in health care
(2003) · Choice Reviews Online · doi:10.5860/choice.40-5843 · Cited by 7,043
A New Initiative on Precision Medicine
Collins, F. S., & Varmus, H. (2015) · New England Journal of Medicine · doi:10.1056/nejmp1500523 · Cited by 5,202
Health Care Disparities
Capps, L. (2003) · JAMA · doi:10.1001/jama.290.18.2487-b · Cited by 4,558
Approximate is Better than “Exact” for Interval Estimation of Binomial Proportions
Agresti, A., & Coull, B. A. (1998) · The American Statistician · doi:10.1080/00031305.1998.10480550 · Cited by 3,223
Participation in Cancer Clinical Trials: Race-, Sex-, and Age-Based Disparities
Murthy, V. H., Krumholz, H. M., & Gross, C. P. (2004) · JAMA · doi:10.1001/jama.291.22.2720 · Cited by 2,078
Cancer
Palandri, F., Breccia, M., Bonifacio, M., Polverelli, N., Elli, E. M., Benevolo, G., Tiribelli, M., Abruzzese, E., Iurlo, A., Heidel, F. H., et al. (2006) · Cancer · doi:10.1002/(issn)1097-0142 · Cited by 1,477
Statistics in Medicine — Reporting of Subgroup Analyses in Clinical Trials
Wang, R., Lagakos, S. W., Ware, J. H., Hunter, D. J., & Drazen, J. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmsr077003 · Cited by 1,445
Barriers to recruiting underrepresented populations to cancer clinical trials: a systematic review
Ford, J. G., Howerton, M. W., Lai, G. Y., Gary, T. L., Bolen, S., Gibbons, M. C., Tilburt, J., Baffi, C., Tanpitukpongse, T. P., Wilson, R. F., et al. (2008) · Cancer · doi:10.1002/cncr.23157 · Cited by 1,083
Racial and Ethnic Disparities in the Receipt of Cancer Treatment
Shavers, V. L. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.5.334 · Cited by 953
OncoTargets and Therapy
(2020) · OncoTargets and Therapy · doi:10.2147/ott · Cited by 787

Show all 30 references

Sorted by citations

Items 201–300 of 570

Mutational landscape of triple-negative breast cancer in African American women
Yao, S., Wei, L., Hu, Q., Liu, S., Manojlovic, Z., Fiorica, P. N., Long, M. D., Zirpoli, G., Cai, Q., Long, J., et al. (2025) · Nature Genetics · doi:10.1038/s41588-025-02322-y · Cited by 12
Meaningful Patient Engagement in Adolescent and Young Adult (AYA) Cancer Research: A Framework for Qualitative Studies
Oveisi, N., Cheng, V., Taylor, D., Bechthold, H., Barnes, M., Jansen, N., McTaggart-Cowan, H. M., Brotto, L. A., Peacock, S. J., Hanley, G. E., et al. (2024) · Current Oncology · doi:10.3390/curroncol31040128 · Cited by 12
Under-Representation and Under-Reporting of Minoritized Racial and Ethnic Groups in Clinical Trials on Immune Checkpoint Inhibitors
Chua, A. V., Delmerico, J., Sheng, H., Huang, X.-W., Liang, E., Yan, L., Gandhi, S., Puzanov, I. J., Jain, P., Sakoda, L. C., et al. (2024) · JCO Oncology Practice · doi:10.1200/op.24.00033 · Cited by 11
Prognostic and Predictive Insights From Genomic Assays for Breast Cancer in Diverse Populations
Abdou, Y. G., Kantor, O., Racz, J. M., Newman, L., Pierce, L. J., & Winer, E. P. (2025) · JAMA Oncology · doi:10.1001/jamaoncol.2025.0178 · Cited by 13
Racial and Ethnic Disparities in Clinical Trial Recruitment in the U.S.
Hong, Y., Tabriz, A. A., & Turner, K. L. (2021) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2021.05.007 · Cited by 11
Diversity, Equity, and Inclusion in Clinical Trials
Keegan, G., Crown, A., & Joseph, K.-A. P. (2022) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2022.08.005 · Cited by 11
Overall Survival in Patients With Multiple Myeloma in the U.S.: A Systematic Literature Review of Racial Disparities
Mikhael, J. R., Cichewicz, A. B., Mearns, E. S., Girvan, A., Pierre, V. J., Rawashdh, N. A., Yellow-Duke, A., Cornell, R. F., & Nixon, M. (2023) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2023.09.009 · Cited by 11
Sociodemographic Characteristics of Adverse Event Reporting in the USA: An Ecologic Study
Muñoz, M. A., Pan, G. J. D., Wei, Y. J., Xiao, H., Delcher, C., Giffin, A., Sadiq, N., & Winterstein, A. G. (2024) · Drug Safety · doi:10.1007/s40264-024-01397-6 · Cited by 11
Race and Ethnicity in Real-World Data Sources: Considerations for Medical Device Regulatory Efforts
Tarver, M. E. (2021) · Journal of Primary Care & Community Health · doi:10.1177/2150132721994040 · Cited by 11
Use of Popular Opinion Leader Models to Disseminate Information About Clinical Trials to Black Individuals With Lupus in Two US Cities
Arneson, L. C., Taber, K. A., Williams, J. N., Ulysse, S. N., Erickson, D. L., Chmiel, J. S., Milaeger, H., Freeman, E., Canessa, P., Song, J., et al. (2022) · Arthritis Care & Research · doi:10.1002/acr.24889 · Cited by 11
Disparities in awareness of and willingness to participate in cancer clinical trials between African American and White cancer survivors
Kumar, G., Kim, J., Farazi, P. A., Wang, H., & Su, D. (2022) · BMC Cancer · doi:10.1186/s12885-022-10082-9 · Cited by 12
Increasing Diversity of Patients in Radiation Oncology Clinical Trials
Roy, E., Chino, F. L., King, B., Madu, C., Mattes, M. D., Morrell, R., Pollard‐Larkin, J., Siker, M., Takita, C., & Ludwig, M. S. (2022) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2022.11.044 · Cited by 12
Lessons From COVID-19: Addressing Health Equity in Cancer Care
Siker, M., Deville, C., Suneja, G., & Winkfield, K. M. (2020) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2020.06.042 · Cited by 11
Do Federal Regulations Affect Gender, Racial, and Ethnic Disparities in Chronic Rhinosinusitis Research?
Spielman, D. B., Schlosser, R. J., Liebowitz, A., Sharma, R. K., Overdevest, J. B., Mattos, J. L., & Gudis, D. A. (2021) · Otolaryngology · doi:10.1177/01945998211021011 · Cited by 10
National enrollment of lung cancer clinical trials is disproportionate based on race and health care access
Kwak, M., Bassiri, A., Jiang, B., Sinopoli, J. N., Tapias‐Vargas, L., Linden, P. A., & Towe, C. W. (2023) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2023.12.012 · Cited by 10
Effective interventions to increase representation of under-served groups in randomised trials in UK and Ireland: a scoping literature review
Biggs, K., Dix, C., Shiely, F., Treweek, S. P., Shepherd, V., Lane, J. A., Green, H., Isaacs, T., Willis, A., & Cooper, C. L. (2024) · NIHR Open Research · doi:10.3310/nihropenres.13524.1 · Cited by 11
Disparities in Care for Patients with Head and Neck Cancer
Marrero‐Gonzalez, A. R., & Graboyes, E. M. (2024) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2024.04.010 · Cited by 10
Mediators of racial and ethnic inequities in clinical trial participation among patients with cancer, 2011-2023
Guadamuz, J. S., Wang, X., Altomare, I. P., Castillo, W. C., Sarkar, S., Mamtani, R., & Calip, G. S. (2024) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkae085 · Cited by 10
How to optimize and evaluate diversity in gynecologic cancer clinical trials: statements from the GCIG Barcelona Meeting
Sehouli, J., Boer, J. D., Brand, A., Oza, A. M., O‘donnell, J., Bennett, K., Glaspool, R., Lee, C. K., Ethier, J., Harter, P., et al. (2024) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2024-005982 · Cited by 9
Underreporting of race/ethnicity in COVID-19 research
Raghav, K. P. S., Anand, S., Gothwal, A., Singh, P., Dasari, A. N., Overman, M. J., & Loree, J. M. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.05.075 · Cited by 10
Self-citation
A systematic review of psycho‐social interventions for individuals with a BRCA1/2 pathogenic variant
Warner, N. Z., Matthews, S., Groarke, A., & McSharry, J. (2021) · Journal of Genetic Counseling · doi:10.1002/jgc4.1436 · Cited by 9
Sociodemographic and clinical factors associated with receipt of biomarker testing in patients with metastatic colorectal cancer
Markt, S. C., Booker, B. D., Bensken, W. P., Schiltz, N. K., Schumacher, F. R., Rose, J., Cooper, G. S., Selfridge, J. E., & Koroukian, S. M. (2022) · Cancer Medicine · doi:10.1002/cam4.4995 · Cited by 10
Demographic reporting and language exclusion in gynecologic oncology clinical trials
Lee, S. S., Dinicu, A., Arthurs, L., Shields, D., Pothuri, B., & Lightfoot, M. D. S. (2023) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2023.09.019 · Cited by 11
Evaluation of Web-Based and In-Person Methods to Recruit Adults With Type 1 Diabetes for a Mobile Exercise Intervention: Prospective Observational Study
Ash, G. I., Griggs, S. A., Nally, L. M., Stults‐Kolehmainen, M., Jeon, S., Brandt, C., Gulanski, B., Spanakis, E. K., Baker, J. S., Whittemore, R., et al. (2021) · JMIR Diabetes · doi:10.2196/28309 · Cited by 10
Development and pilot test of a physician-focused cancer clinical trials communication training intervention
Eggly, S. S., Manning, M. A., Senft, N., Moore, T. F., Albrecht, T. L., Penner, L. A., Heath, E. I., Carducci, M. A., Lansey, D. G., & Hamel, L. M. (2021) · PEC Innovation · doi:10.1016/j.pecinn.2021.100012 · Cited by 10
Action for Increasing Diversity, Market Access, and Capacity in Oncology Registration Trials—Is Africa the Answer? Report From a Satellite Session of the Accelerating Anti-Cancer Agent Development and Validation Workshop
Kizub, D., Manner, C. K., Graef, K. M., Abubakar, B., Orem, J., Odedina, F. T., Adeyeye, C. M., Nakigudde, G., Ayalew, K., Kalidas, C., et al. (2022) · JCO Global Oncology · doi:10.1200/go.22.00117 · Cited by 11
Selection and Prejudice: Addressing Clinical Trial Disparities With a Review of Current Shortcomings and Future Directions
Corrigan, K. L., Rooney, M. K., Kouzy, R., Manzar, G. S., Thomas, C. R., & Ludmir, E. B. (2023) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2023.06.002 · Cited by 9
Patient Recruitment in Clinical Trials: Areas of Challenges and Success, a Practical Aspect at the Private Research Site
Wandile, P. M. (2023) · Journal of Biosciences and Medicines · doi:10.4236/jbm.2023.1110010 · Cited by 9
The Diversity of Research Participants in Randomized Controlled Trials and Observational Studies Conducted by the Canadian Critical Care Trials Group
Mehta, S., Ahluwalia, A., Ahluwalia, A. K., Burns, K. E. A., O’Hearn, K., Maratta, C., Menon, K., Rochwerg, B. N., Murthy, S., Fowler, R. A., et al. (2024) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202312-1074oc · Cited by 9
Tailored approach to participant recruitment and retention to maximize health equity in pediatric cancer research
Bates, C. R., Gilbert, R. M., Dean, K. M., August, K. J., Befort, C. A., Ward, S., Gibson, M., & Gillette, M. L. D. (2024) · BMC Medical Research Methodology · doi:10.1186/s12874-024-02287-2 · Cited by 11
Feasibility and Effectiveness of Recruiting Latinos in Decídetexto—A Smoking Cessation Clinical Trial from an Emergency Department Patient Registry
Arana‐Chicas, E., Cartujano‐Barrera, F., Ogedegbe, C., Ellerbeck, E. F., Cox, L. S., Graves, K. D., Díaz, F. J., Catley, D., & Cupertino, A. P. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph182010859 · Cited by 9
A lack of race and ethnicity data in the treatment of hereditary hemorrhagic telangiectasia: a systematic review of intravenous bevacizumab efficacy
Galiatsatos, P., Wilson, C., O’Brien, J., Gong, A. J., Angiolillo, D., Johnson, J. R., Myers, C. N., Strout, S. E., Mathai, S. C., Robinson, G., et al. (2022) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-022-02371-0 · Cited by 8
Particles and Prejudice: Nanomedicine Approaches to Reducing Health Disparities in Endometrial Cancer
Rowlands, C. E., Folberg, A. M., Beickman, Z. K., Devor, E. J., Leslie, K. K., & Givens, B. E. (2023) · Small · doi:10.1002/smll.202300096 · Cited by 10
Trends in participant race and sex reporting in lung cancer phase III clinical trials
Aslam, F. N., Manochakian, R., Lou, Y., Colón‐Otero, G., & Sher, T. (2023) · Cancer Reports · doi:10.1002/cnr2.1856 · Cited by 9
Creating Equitable and Inclusive Clinical Trials for Multiple Myeloma
Hartley-Brown, M. A., Cole, C. E., Price, P., Andreini, M., Mulligan, G., Young, A. Q., & Cho, H. J. (2023) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2023.09.004 · Cited by 9
Diversity in clinical trials in Europe and the USA: a review of a pharmaceutical company’s data collection, reporting, and interpretation of race and ethnicity
Candelario, N. M., Major, J., Dreyfus, B., Sattler, D., Paulucci, D. J., Misra, S., Micsinai, M., & Kuri, L. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.09.3107 · Cited by 9
NCI–Clinical Trial Accrual in a Community Network Affiliated with a Designated Cancer Center
Kim, D. J., Otap, D., Ruel, N. H., Gupta, N. K., Khan, N., & Dorff, T. B. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061970 · Cited by 9
Social determinants of health inequalities in early phase clinical trials in Northern England
Rae, S., Shaya, S., Taylor, E., Hoben, J., Oluwashegun, D., Lowe, H., Haris, N. M., Bashir, S., Oing, C., Krebs, M., et al. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02765-w · Cited by 7
Are community oncology practices with or without clinical research programs different? A comparison of patient and practice characteristics
Altomare, I. P., Wang, X., Kaur, M., Guadamuz, J. S., Falk, S., Xiao, F., Meropol, N. J., & Zhao, Y. (2024) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkae060 · Cited by 8
Exploring Racial Disparities in Awareness and Perceptions of Oncology Clinical Trials: Cross-Sectional Analysis of Baseline Data From the mychoice Study
Hoadley, A., Fleisher, L. G., Kenny, C., Kelly, P. J. A., Ma, X., Wu, J., Guerra, C. E., Leader, A. E., Alhajji, M., D’Avanzo, P. A., et al. (2024) · JMIR Cancer · doi:10.2196/56048 · Cited by 8
NHS-Galleri trial: Enriched enrolment approaches and sociodemographic characteristics of enrolled participants
Swanton, C., Bachtiar, V., Mathews, C. S., Brentnall, A. R., Lowenhoff, I., Waller, J., Bomb, M., McPhail, S., Pinches, H., Smittenaar, R., et al. (2025) · Clinical Trials · doi:10.1177/17407745241302477 · Cited by 8
Unequal representation? A cross-sectional analysis of age, sex, race, and ethnicity in clinical trials of classic psychedelics
Świeczkowski, D., Kwaśny, A., Ciurkowska, P., Pruc, M., Szarpak, Ł., & Cubała, W. J. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251353250 · Cited by 8
Evaluation of Diversity of Clinical Trials Informing Health Technology Assessments in the United States: A 5-Year Analysis of Institute for Clinical and Economic Review Assessments
Agboola, F. O., Wright, A. C., Herron-Smith, S., Mathur, D., & Rind, D. M. (2023) · Value in Health · doi:10.1016/j.jval.2023.05.014 · Cited by 8
Trends in Patient Representation in Low Back Pain Pharmacological Randomized Clinical Trials, 2011 to 2020: A Systematic Review
Jiang, T., Edwards, K. A., Dildine, T. C., You, D. S., Nguyen, T., Pascual, A. P., & Falasinnu, T. (2024) · Journal of Pain · doi:10.1016/j.jpain.2023.12.013 · Cited by 8
Incorporating health equity into value assessment: frameworks, promising alternatives, and future directions
Diaby, V., Ali, A. A., Babcock, A., Fuhr, J. P., & Braithwaite, D. (2021) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2021.27.9-a.s22 · Cited by 8
Characteristics of Clinical Trial Sites for Novel Transcatheter Mitral and Tricuspid Valvular Therapies
Nathan, A. S., Reddy, K. P., Yang, L., Eberly, L. A., Dayoub, E. J., Khatana, S. A. M., Julien, H. M., Desai, N. D., Szeto, W. Y., Herrmann, H. C., et al. (2022) · JAMA Cardiology · doi:10.1001/jamacardio.2022.4457 · Cited by 8
Understanding drivers of the Black:White breast cancer mortality gap: A call for more robust definitions
Jones, V., Kruper, L. L., Mortimer, J. E., Ashing, K. T., & Seewaldt, V. L. (2022) · Cancer · doi:10.1002/cncr.34243 · Cited by 8
Diversified Innovations in the Health Sciences - Proposal for a Diversity Minimal Item Set (DiMIS)Preprint
Stadler, G., Chesaniuk, M., Haering, S., Roseman, J., Straßburger, V. M., & Schraudner, M. (2022) · doi:10.31234/osf.io/bjyms · Cited by 8
Why location matters: associations between county-level characteristics and availability of National Cancer Oncology Research Program and National Cancer Institute sites
Caston, N. E., Williams, C., Levitan, E. B., Griffin, R. L., Azuero, A., Wheeler, S. B., & Rocque, G. B. (2024) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkae038 · Cited by 7
Uncovering multilevel drivers of cancer disparities among Latinos in the United States
Ramírez, A. G., Munoz, E., Rodríguez-Rodríguez, L., Bernal‐Mizrachi, L., Chalela, P., Lopez, J. A., Pinheiro, P. S., Segarra-Vasquez, B., Talavera, G., Carvajal‐Carmona, L. G., et al. (2025) · Frontiers in Public Health · doi:10.3389/fpubh.2025.1591074 · Cited by 7
ASCO State of Cancer Care in America Special Report 2025: Access to Cancer Clinical Trials in the United States
Balogh, E. P., Levit, L. A., Unger, J. M., Accordino, M. K., Chism, D. D., Kirkwood, M. K., Parsons, H. M., Patel, M. I., Peppercorn, J. M., Polite, B. N., et al. (2025) · JCO Oncology Practice · doi:10.1200/op-25-00233 · Cited by 10
Self-citation
The ESMO/SIOG Cancer in the Elderly Working Group pragmatic strategies for clinical trial designs and endpoints in older adults with cancer
Baldini, C., Mislang, A. R., Cheung, K., Pilleron, S., Wildiers, H., Rostoft, S., Neuendorff, N. R., Frélaut, M., Kanesvaran, R., Papamichael, D., et al. (2026) · ESMO Open · doi:10.1016/j.esmoop.2025.105940 · Cited by 8
Reflection on Black and Ethnic Minority Participation in Clinical Trials
Iyizoba-Ebozue, Z., Fatimilehin, A., Mbanu, P., & Adeleke, S. M. (2022) · Clinical Oncology · doi:10.1016/j.clon.2022.07.006 · Cited by 7
Research Ambassador Program: An innovative educational approach to addressing underrepresentation of minority populations in clinical research
Wolfe, N., Rubio-Diaz, M., Garcia, A., Calderon, S., & Kipke, M. D. (2022) · Journal of Clinical and Translational Science · doi:10.1017/cts.2022.496 · Cited by 7
Disparities in care of older adults of color with cancer: A narrative review
Dotan, E., Lynch, S. M., Ryan, J. C., & Mitchell, E. P. (2024) · Cancer Medicine · doi:10.1002/cam4.6790 · Cited by 6
Empagliflozin and Risk of Incident Gout: Analysis from the EMPagliflozin Comparative Effectiveness and SafEty (EMPRISE) Cohort Study
Tesfaye, H., Wang, K. M., Zabotka, L. E., Wexler, D. J., Schmedt, N., Koeneman, L., SEMAN, L. J., Paik, J. M., & Patorno, E. (2024) · Journal of General Internal Medicine · doi:10.1007/s11606-024-08793-9 · Cited by 7
Globalization of clinical research in oncology: Status, challenges, and future directions
Vuger, A. T., Šeparović, R., Tolaney, S. M., & Trapani, D. (2024) · Journal of Cancer Policy · doi:10.1016/j.jcpo.2024.100500 · Cited by 7
Critically appraising for antiracism
Naicker, R. (2022) · Education for Information · doi:10.3233/efi-220052 · Cited by 7
Use of Bland-Altman Analysis to Examine the Racial and Ethnic Representativeness of Study Populations in Community-Based Pediatric Health Research
Krobath, D. M., Naumova, E. N., Cuevas, A. G., Sacheck, J. M., Wilson, N. L. W., & Economos, C. D. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.12920 · Cited by 7
Challenging assumptions about the demographics of eosinophilic gastrointestinal diseases: A systematic review
Chehade, M., Wright, B. L., Walsh, S., Bailey, D. D., Muir, A. B., Klion, A. D., Collins, M. H., Davis, C. M., Furuta, G. T., Gupta, S. K., et al. (2024) · Journal of Allergy and Clinical Immunology Global · doi:10.1016/j.jacig.2024.100260 · Cited by 7
How subgroup analyses can miss the trees for the forest plots: A simulation study
Webster‐Clark, M., Baron, J. A., Funk, M. J., & Westreich, D. J. (2020) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2020.06.020 · Cited by 8
Are novel glucose‐lowering agents' cardiorenal benefits generalizable to individuals of Black race? A meta‐trial sequential analysis to address disparities in cardiovascular and renal outcome trials enrolment
Tang, H., Kimmel, S. E., Hernandez, I., Brooks, M. M., Cusi, K. J., Smith, S. M., Shi, W., Winterstein, A. G., Magnani, J. W., & Guo, J. S. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14540 · Cited by 7
Disparities and Inequities Among Patients with Central Nervous System Tumor
Chukwueke, U. N., Hervey‐Jumper, S. L., & Porter, A. B. (2021) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2021.10.002 · Cited by 7
Clinical trials-related knowledge, attitudes, and behaviors among Black and Latina women: A randomized controlled trial of the Women United: Clinical Trials and the Fight Against Breast Cancer Program
Merz, E. L., Riley, N. E., Malcarne, V. L., & Sadler, G. R. (2022) · Journal of Cancer Education · doi:10.1007/s13187-022-02162-y · Cited by 6
Patient-reported outcomes of patients with myelofibrosis or essential thrombocythemia enrolled in the MOST study
Ritchie, E. K., Al-Janadi, A., Kessler, C. M., Scherber, R. M., Kalafut, T., Ren, H., & Mesa, R. A. (2022) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2022.2113531 · Cited by 7
Socioeconomic and Demographic Disparities in Immunotherapy Utilization for Advanced Kidney and Bladder Cancer
Holland, L. C., Bhanvadia, R. R., Ibeziako, N., Taylor, J. I., Gerlt, D., Chaplin, I., Bagrodia, A., Desai, N. B., Gaston, K. E., Lotan, Y., et al. (2024) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2024.06.012 · Cited by 6
Disparities in Utilization of Immune Checkpoint Inhibitor Therapy Among Older Patients With Advanced Non–Small Cell Lung Cancer: A SEER-Medicare Analysis
Yang, D., Karanth, S. D., Yoon, H., Yang, J. J., Lou, X., Bian, J., Zhang, D., Guo, Y. M., Yaghjyan, L., Akinyemiju, T., et al. (2024) · JCO oncology advances. · doi:10.1200/oa.24.00008 · Cited by 6
Race and age disparities in randomized trials of acute myeloid leukemia: a systematic review and meta-analysis
Loeb, N., Katsnelson, O., Jain, A., Tahvildar, P., Teitelbaum, D. H., & Garcia‐Horton, A. (2025) · Blood Neoplasia · doi:10.1016/j.bneo.2025.100070 · Cited by 6
Clinical Trial Discussion and Participation in a Breast Cancer Cohort by Race and Ethnicity
Chen, N., Freeman, J. Q., Zhao, F., Goldberg, L. A., Yarlagadda, S. R., Terman, E., Huo, D., & Nanda, R. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.15205 · Cited by 6
Global Challenges in Paediatric Acute Lymphoblastic Leukaemia
Krishnan, S., & Saha, V. (2025) · Acta Haematologica · doi:10.1159/000547506 · Cited by 6
Race/Ethnicity, Gender, and Socioeconomic Status Representation in U.S.-Based Randomized Controlled Trials of Tinnitus: A Systematic Review
Deshpande, S. B., & Deshpande, A. K. (2022) · American Journal of Audiology · doi:10.1044/2022_aja-21-00244 · Cited by 6
Examining uncertainty management in the clinical trial experiences of African American and Black Caribbean participants and the coordinators who recruit them
Wright, K. O., Deal, B. E., Harrison, T. R., Malova, E., Jia, X., & Morgan, S. E. (2023) · SSM - Qualitative Research in Health · doi:10.1016/j.ssmqr.2023.100231 · Cited by 5
Development of a Machine Learning Model to Identify Colorectal Cancer Stage in Medicare Claims
Finn, C. B., Sharpe, J. E., Tong, J., Kaufman, E. J., Wachtel, H., Aarons, C. B., Weissman, G. E., & Kelz, R. R. (2023) · JCO Clinical Cancer Informatics · doi:10.1200/cci.23.00003 · Cited by 6
A Ground’s-Eye View on Racial and Ethnic Disparities in Cancer Clinical Trial Participation
Unger, J. M. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.22436 · Cited by 6
Self-citation
Catalogue of bias: racial bias
Naicker, R., & Nunan, D. (2023) · BMJ Evidence-Based Medicine · doi:10.1136/bmjebm-2023-112400 · Cited by 6
Meta‐analysis of sex and racial subgroup participation rates and differential treatment effects for trials in solid tumor malignancies leading to US Food and Drug Administration registration between 2010 and 2021
Wilson, B. E., Nadler, M. B., Desnoyers, A., Booth, C. M., & Amir, E. (2023) · Cancer · doi:10.1002/cncr.35035 · Cited by 6
Racial Differences in Cutaneous Events Among Patients Receiving Enfortumab Vedotin
Vlachou, E., Mamtani, R., Hahn, N. M., Johnson, B. A., Hoffman-Censits, J. H., & Nimgaonkar, V. U. (2024) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2024.102090 · Cited by 6
A scoping review of the unique landscape and challenges associated with dementia in the Western Pacific region
Devenney, E. M., Nguyen, Q. A. N., Tse, N. Y., Kiernan, M. C., & Tan, R. H. (2024) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2024.101192 · Cited by 6
Clinical Trials and Breast Cancer Disparities
Bea, V. J., Taiwo, E. O., Balogun, O., & Newman, L. A. (2021) · Current Breast Cancer Reports · doi:10.1007/s12609-021-00422-2 · Cited by 6
Uneven global and racial representation in major orthopaedic clinical trials: Trends over a decade
George, J., Gautam, D., Sugumar, P. A. A., Janardhanan, R., Kabra, A. P., & Malhotra, R. (2022) · Journal of Clinical Orthopaedics and Trauma · doi:10.1016/j.jcot.2022.101894 · Cited by 6
Challenges in recording race and ethnicity data in biomedical research: the French and Swedish perspectives
Yordanov, Y., Louarn, A. L., & Khoshnood, A. (2023) · European Journal of Emergency Medicine · doi:10.1097/mej.0000000000001035 · Cited by 6
Partnering With All Patients: Ensuring Shared Decision Making and Evidence-Based Management for Underrepresented Groups With Multiple Myeloma
Cerchione, C., Grant, S. J., & Ailawadhi, S. (2023) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_390202 · Cited by 7
Results from a Real-World Multicenter Analysis of 482 Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Look at Racial Differences
Barrientos, J. C., Ayed, A. O., Cha, A., Du, S., Fang, B. S., Hall, R., Marks, S. M., Peng, E., Rhodes, J. M., Ryan, K. J., et al. (2023) · Targeted Oncology · doi:10.1007/s11523-023-00988-0 · Cited by 6
A systematic review of ethnic minority participation in randomised controlled trials of systemic therapies for gynecological cancers
Steventon, L., Nicum, S., Man, K. K. C., Chaichana, U., Wei, L., & Chambers, P. (2024) · Gynecologic Oncology · doi:10.1016/j.ygyno.2024.01.052 · Cited by 6
The potential role of precision medicine to alleviate racial disparities in prostate, bladder and renal urological cancer care
Sindhu, K. K., Dovey, Z. S., Thompson, M., Nehlsen, A. D., Skalina, K. A., Małachowska, B., Hasan, S., Guha, C., Tang, J., & Salgado, L. R. (2024) · BJUI Compass · doi:10.1002/bco2.323 · Cited by 5
Harnessing policy to promote inclusive medical product evidence: development of a reference standard and structured audit of clinical trial diversity policies
Miller, J. E., Pelletiers, W., Suttiratana, S. C., Mensah, M. O., Schwartz, J. L., Ramachandran, R., Gross, C. P., & Ross, J. S. (2024) · BMJ Medicine · doi:10.1136/bmjmed-2024-000920 · Cited by 6
Integration of electronic pathology reporting with clinical trial matching for advanced prostate cancer
Borno, H. T., Duffy, C., Zhang, S., Canchola, A. J., Loya, Z., Golden, T. R., Oh, D. L., Odisho, A. Y., & Gomez, S. L. (2021) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2020.12.010 · Cited by 6
Racial and sex representation in clinical trials: Where are we in abdominal organ transplantation?
Zaldana, A., Barhouma, S., Rocque, B., Barbetta, A., Goldbeck, C. S., Sher, L. S., & Emamaullee, J. A. (2021) · American Journal of Transplantation · doi:10.1111/ajt.16619 · Cited by 5
Age, racial, and ethnic disparities in reported clinical studies involving brachytherapy
Ladbury, C. J., Liu, J., Novak, J., Amini, A., & Glaser, S. (2021) · Brachytherapy · doi:10.1016/j.brachy.2021.06.150 · Cited by 6
Exploring cancer care needs for Latinx adults: a qualitative evaluation
Rodriguez, G. M., Leach, M., Osorio, J., Villicana, G., Koontz, M. Z., Wood, E. H., Durón, Y., O’Brien, D. G., Rosas, L. G., & Patel, M. I. (2022) · Supportive Care in Cancer · doi:10.1007/s00520-022-07518-0 · Cited by 9
Valuing Black lives and the ‘Good Death’ in the United States
Cain, C. (2021) · Sociology of Health & Illness · doi:10.1111/1467-9566.13310 · Cited by 6
For better drugs, diversify clinical trials
Bumpus, N. N. (2021) · Science · doi:10.1126/science.abe2565 · Cited by 6
Historic Abuses, Present Disparities, and Systemic Racism: Threats to Surrogate Decision-making for Critical Care Research Enrollment
Krutsinger, D. C., Courtright, K. R., & Estabrooks, P. A. (2021) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202103-386ed · Cited by 6
Racially Conscious Cancer Screening Guidelines
Perez, N. P., Baez, Y. A., Stapleton, S. M., Muniappan, A., Oseni, T. O., Goldstone, R. N., & Chang, D. C. (2020) · Annals of Surgery · doi:10.1097/sla.0000000000003983 · Cited by 5
Enhancing accessibility and impact of digitally enabled clinical trials: the WeShare engagement and equity toolkit
Franzoi, M. A., Everhard, S., Gillanders, E., & Vaz-Luis, I. (2025) · ESMO Real World Data and Digital Oncology · doi:10.1016/j.esmorw.2025.100175 · Cited by 5
Individualized Medicine in the Era of Artificial Intelligence
Lazaridis, K. N., Klee, E. W., Curry, T. B., Ortega, V. E., Bobo, W. V., Athreya, A. P., & Samsonraj, R. M. (2025) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2025.07.028 · Cited by 6
Disparities in clinical trial participation among older adult Medicare beneficiaries with hematologic malignancies from 2006 to 2019: A SEER–Medicare analysis
Gong, I. Y., Soto, M. J., Rafinejad‐Farahani, B., Unger, J. M., Conti, R. M., Guerra, C. E., Oza, A. M., Rosenthal, M. B., & Rodin, D. L. (2025) · Cancer · doi:10.1002/cncr.70204 · Cited by 5
Self-citation
Do Current Lung Cancer Clinical Trials Represent All Patient Populations Including Minorities?
Nemala, A., Ullah, A., Yacur, M., & Karim, N. A. (2023) · Clinical Lung Cancer · doi:10.1016/j.cllc.2023.08.003 · Cited by 5
Community engagement strategies for population health research with culturally diverse adults
Webb, F. J., Bilello, L. A., Vaccaro, J. A., Jones, R. E., Neff, D. F., & Gaillard, T. R. (2023) · Journal of Medicine Surgery and Public Health · doi:10.1016/j.glmedi.2023.100037 · Cited by 5
Trends and Rates of Reporting of Race, Ethnicity, and Social Determinants of Health in Spine Surgery Randomized Clinical Trials
Solomon, E., Gupta, M., Su, R. L., Reinhart, N. M., Battistoni, V., Mittal, A. M., Bronheim, R. S., Silva-Aponte, J. A., Reyes, M. C., Hawkins, D., et al. (2024) · Clinical Spine Surgery A Spine Publication · doi:10.1097/bsd.0000000000001675 · Cited by 5

Authors: Loree, J. M., Anand, S., Dasari, A., Unger, J. M., Gothwal, A., Ellis, L. M., Varadhachary, G., Kopetz, S., Overman, M. J., & Raghav, K.
Affiliations: BC Cancer Agency (CA)
The University of Texas MD Anderson Cancer Center (US)
Fred Hutch Cancer Center (US)
Baylor University (US)
Corresponding author: Raghav, Kanwal
ORCID: Loree, Jonathan M.
Dasari, Arvind
Unger, Joseph M.
Ellis, Lee M.
Kopetz, Scott
Overman, Michael J.
Raghav, Kanwal
Venue: JAMA Oncology
Publisher: American Medical Association (AMA)
Published: 2019-10-10
Volume: 5
Issue: 10
Pages: e191870
ISSN: 2374-2437 (ISSN-L)
DOI: 10.1001/jamaoncol.2019.1870
PMC: PMC6696743
OpenAlex: W2969031691
Semantic Scholar: 7ef4c8e3b560e1041587d5370115a6db62f37be5
Cited by: 570
References: 30
Citations by year: 2026: 59 · 2025: 67 · 2024: 89 · 2023: 104 · 2022: 120 · 2021: 99 · 2020: 31
FWCI: 57.56
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: JAMA Oncology (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: National Cancer Institute (UG1CA189974, P30CA016672)
Topics: Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Ethics in Clinical Research
Social Sciences › Anthropology › Race, Genetics, and Society
Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
Keywords: racial disparities, oncology drug approval, FDA drug approval, cancer clinical trials, health equity, racial disparities in cancer outcomes, racial disparities in cancer survival, racial disparities in cancer incidence, racial disparities in cancer mortality

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks